Therapeutic antibodies to Marburg virus
AssigneeThe Government of the United States, as represented by the Secretary of the Army
InventorsPhilippe Thullier, Jeffrey Froude, II, John Dye, Jr.
Life of this patent
Estimating the term…
Abstract
Provided here are immunoglobulins and compositions containing one or more of said immunoglobulins reactive to a strain of Marburg virus. The immunoglobulins and compositions comprising said immunoglobulins can be used prophylactically to prevent a Marburg virus infection or to treat a patient that has been exposed to a Marburg virus in order to reduce a symptom.
Claims19
A composition comprising a reactive anti-Marburg immunoglobulin and a pharmaceutically acceptable carrier, wherein the immunoglobulin comprises VH complementarity determining regions (CDRs) of:
- a VH CDR1 corresponding to amino acid residues of 26-33 of SEQ ID NO:
- 1;
- a VH CDR2 corresponding to amino acid residues of 51-58 of SEQ ID NO:
- 1;
- and
- a VH CDR3 corresponding to amino acid residues of 97-107 of SEQ ID NO:
- 1;
- and VL CDRs of:
- a VL CDR1 corresponding to amino acid residues of 27-32 of SEQ ID NO:
- 2;
- a VL CDR2 corresponding to amino acid residues of 50-52 of SEQ ID NO:
- 2;
- and
- a VL CDR3 corresponding to amino acid residues of 89-97 of SEQ ID NO:
- 2.
An immunoglobulin that is reactive to a strain of Marburg virus, wherein the immunoglobulin is selected from the group consisting of:
- (a) an immunoglobulin comprising VH complementarity determining regions (CDRs) of:
- a VH CDR1 corresponding to amino acid residues of 26-33 of SEQ ID NO:
- 1;
- a VH CDR2 corresponding to amino acid residues of 51-58 of SEQ ID NO:
- 1;
- and
- a VH CDR3 corresponding to amino acid residues of 97-107 of SEQ ID NO:
- 1;
- and VL CDRs of:
- a VL CDR1 corresponding to amino acid residues of 27-32 of SEQ ID NO:
- 2;
- a VL CDR2 corresponding to amino acid residues of 50-52 of SEQ ID NO:
- 2;
- and
- a VL CDR3 corresponding to amino acid residues of 89-97 of SEQ ID NO:
- 2;
- (b) immunoglobulin R4G7 having a VH of SEQ ID NO:
- 9 and a VL of SEQ ID NO:
- 10;
- (c) immunoglobulin R4G10 having a VH of SEQ ID NO:
- 11 and a VL of SEQ ID NO:
- 12;
- (d) immunoglobulin R4G11 having a VH of SEQ ID NO:
- 13 and a VL of SEQ ID NO:
- 14;
- (e) immunoglobulin R3C4 having a VH of SEQ ID NO:
- 15 and a VL of SEQ ID NO:
- 16;
- (f) immunoglobulin R4G8 having a VH of SEQ ID NO:
- 17 and a VL of SEQ ID NO:
- 18;
- (g) immunoglobulin R3D4 having a VH of SEQ ID NO:
- 19 and a VL of SEQ ID NO:
- 20;
- (h) immunoglobulin R3G2 having a VH of SEQ ID NO:
- 21 and a VL of SEQ ID NO:
- 22;
- (i) immunoglobulin R3G5 having a VH of SEQ ID NO:
- 23 and a VL of SEQ ID NO:
- 24;
- (j) immunoglobulin R4H12 having a VH of SEQ ID NO:
- 25 and a VL of SEQ ID NO:
- 26;
- and
- (k) immunoglobulin R3H2 having a VH of SEQ ID NO:
- 27 and a VL of SEQ ID NO:
- 28.
Dependencies are inferred from the claim text.